TrialDiabetes care2025

Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.

Gregory G Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.